Francisco Javier
López Jiménez
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario Central de Asturias
Oviedo, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Central de Asturias (11)
2024
-
18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study
Expert Review of Hematology, Vol. 17, Núm. 1-3, pp. 95-100
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain
Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8
2023
-
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study
British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193
2021
-
Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group
Transplant Infectious Disease, Vol. 23, Núm. 4
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620
-
Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study
British Journal of Haematology
2017
-
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59
-
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study
PLoS ONE, Vol. 12, Núm. 9
2014
-
Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation
Haematologica, Vol. 99, Núm. 10, pp. 1632-1637
2011
-
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab
Expert Review of Hematology, Vol. 4, Núm. 1, pp. 9-16